EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 33 / Numéro 5 (Mai 2017) Med Sci (Paris), 33 5 (2017) 528-533 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 33, Numéro 5, Mai 2017
Page(s) 528 - 533
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20173305017
Publié en ligne 14 juin 2017
  1. Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit Care Med 2010 ; 38 : e91–e97. [CrossRef] [PubMed] [Google Scholar]
  2. Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis 2006 ; 6 : 303–312. [CrossRef] [PubMed] [Google Scholar]
  3. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: Implications for pandemic influenza preparedness. J Infect Dis 2008 ; 198 : 962–970. [CrossRef] [PubMed] [Google Scholar]
  4. Mccullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Micro 2014 ; 12 : 252–262. [CrossRef] [Google Scholar]
  5. Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis 2011 ; 203 : 6–10. [CrossRef] [PubMed] [Google Scholar]
  6. Davidson S, Mc Cabe TM, Crotta S, et al. IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment. EMBO Mol Med 2016 ; 8 : 1099–1112. [CrossRef] [PubMed] [Google Scholar]
  7. Darwish I, Mubareka S, Liles WC. Immunomodulatory therapy for severe influenza. Expert Rev Anti Infect Ther; 9 : 807–822. [Google Scholar]
  8. Campigotto A, Mubareka S. Influenza-associated bacterial pneumonia; managing and controlling infection on two fronts. Expert Rev Anti Infect Ther 2015 ; 13 : 55–68. [CrossRef] [PubMed] [Google Scholar]
  9. Brun-Buisson C, Richard J-CM, Mercat A, et al. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011 ; 183 : 1200–1206. [CrossRef] [PubMed] [Google Scholar]
  10. Oldstone MBA, Rosen H. Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule. Curr Top Microbiol Immunol 2014 ; 378 : 129–147. [PubMed] [Google Scholar]
  11. Sugiyama MG, Armstrong SM, Wang C, et al. The Tie2-agonist vasculotide rescues mice from influenza virus infection. Sci Rep 2015 ; 5 : 11030. [CrossRef] [PubMed] [Google Scholar]
  12. Li L, Chong HC, Ng SY, et al. Angiopoietin-like 4 increases pulmonary tissue leakiness and damage during influenza pneumonia. Cell Rep 2015 ; 10 : 654–663. [PubMed] [Google Scholar]
  13. Monticelli LA, Sonnenberg GF, Abt MC, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 2011 ; 12 : 1045–1054. [CrossRef] [PubMed] [Google Scholar]
  14. Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 2011 ; 12 : 383–390. [CrossRef] [PubMed] [Google Scholar]
  15. Paget C, Ivanov S, Fontaine J, et al. Interleukin-22 is produced by invariant natural killer T lymphocytes during influenza A virus infection: potential role in protection against lung epithelial damages. J Biol Chem 2012 ; 287 : 8816–8829. [CrossRef] [PubMed] [Google Scholar]
  16. Braza F, Dirou S, Forest V, et al. Mesenchymal stem cells induce suppressive macrophages through phagocytosis in a mouse model of asthma. Stem Cells 2016 ; 34 : 1836–1845. [CrossRef] [PubMed] [Google Scholar]
  17. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009 ; 302 : 2323–2329. [CrossRef] [PubMed] [Google Scholar]
  18. Noah MA, Peek GJ, Finney SJ, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA 2011 ; 306 : 1659. [CrossRef] [PubMed] [Google Scholar]
  19. Roquilly A, Marret E, Abraham E, Asehnoune K. Pneumonia prevention to decrease mortality in intensive care unit: A systematic review and meta-analysis. Clin Infect Dis 2014 ; 60 : 64–75. [Google Scholar]
  20. Metzger DW, Sun K. Immune dysfunction and bacterial coinfections following influenza. J Immunol 2013 ; 191 : 2047–2052. [PubMed] [Google Scholar]
  21. Snelgrove RJ, Godlee A, Hussell T. Airway immune homeostasis and implications for influenza-induced inflammation. Trends Immunol 2011 ; 32 : 328–334. [PubMed] [Google Scholar]
  22. Mcnamee LA, Harmsen AG. Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary Streptococcus pneumoniae infection. Infect Immun 2006 ; 74 : 6707–6721. [CrossRef] [PubMed] [Google Scholar]
  23. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-γ during recovery from influenza infection. Nat Med 2008 ; 14 : 558–564. [CrossRef] [PubMed] [Google Scholar]
  24. Shahangian A, Chow EK, Tian X, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 2009 ; 119 : 1910–1920. [PubMed] [Google Scholar]
  25. Barthelemy A, Ivanov S, Fontaine J, et al. Influenza A virus-induced release of interleukin-10 inhibits the anti-microbial activities of invariant natural killer T cells during invasive pneumococcal superinfection. Mucosal Immunol 2016 ; 4 : 1–10. [EDP Sciences] [Google Scholar]
  26. Kudva A, Scheller EV, Robinson KM, et al. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol 2011 ; 186 : 1666–1674. [PubMed] [Google Scholar]
  27. Cao J, Wang D, Xu F, et al. Activation of IL-27 signalling promotes development of postinfluenza pneumococcal pneumonia. EMBO Mol Med 2014 ; 6 : 120–140. [CrossRef] [PubMed] [Google Scholar]
  28. Ivanov S, Paget C, Trottein F. Role of non-conventional T lymphocytes in respiratory infections: The case of the Pneumococcus. Plos Pathog. 2014 ; 10 : e1004300–e1004311. [PubMed] [Google Scholar]
  29. Li W, Moltedo B, Moran TM. Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of T cells. J Virol 2012 ; 86 : 12304–12312. [CrossRef] [PubMed] [Google Scholar]
  30. Van der Sluijs KF, Nijhuis M, Levels JHM, et al. Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia. J Infect Dis 2006 ; 193 : 214–222. [CrossRef] [PubMed] [Google Scholar]
  31. Rynda-Apple A, Robinson KM, Alcorn JF. Influenza and bacterial superinfection: Illuminating the immunologic mechanisms of disease. Infect Immun 2015 ; 83 : 3764–3770. [CrossRef] [PubMed] [Google Scholar]
  32. Broquet A, Roquilly A, Jacqueline C, et al. Depletion of natural killer cells increases mice susceptibility in a Pseudomonas aeruginosa pneumonia model. Crit Care Med 2014 ; 42 : e441–e450. [CrossRef] [PubMed] [Google Scholar]
  33. Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009 ; 180 : 640–648. [CrossRef] [PubMed] [Google Scholar]
  34. Didierlaurent A, Goulding J, Patel S, et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 2008 ; 205 : 323–329. [CrossRef] [PubMed] [Google Scholar]
  35. Porte R, Fougeron D, Muñoz-Wolf N, et al. A Toll-like receptor 5 agonist improves the efficacy of antibiotics in treatment of primary and influenza virus-associated pneumococcal mouse infections. Antimicrob Agents Chemother 2015 ; 59 : 6064–6072. [CrossRef] [PubMed] [Google Scholar]
  36. Reppe K, Radünzel P, Dietert K, et al. Pulmonary immunostimulation with MALP-2 in influenza virus-infected mice increases survival after pneumococcal superinfection. Infect Immun 2015 ; 83 : 4617–4629. [CrossRef] [PubMed] [Google Scholar]
  37. Barthelemy A, Ivanov S, Hassane M, et al. Exogenous activation of invariant natural killer T cells by α-galactosylceramide reduces pneumococcal outgrowth and dissemination postinfluenza. MBio 2016 ; 7 : 6. [Google Scholar]
  38. Zylberman P. Comme en 1918 ! La grippe « espagnole » et nous. Med Sci (Paris) 2006 ; 22 : 767–770. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  39. Lina B. Potentiel pandémique des virus influenza aviaires circulant actuellement et ayant des caractéristiques proches du virus de 1918. Med Sci (Paris) 2014 ; 30 : 851–853. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  40. Coignard-Biehler H, Lortholary O. Cabale contre la vaccination anti-H1N1: est-elle justifiée ? Med Sci (Paris) 2009 ; 25 : 967–970. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.